News
GlobalData on MSN16h
EC approves AstraZeneca’s acalabrutinib combo for CLLThe EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback